Domestic drug companies to keep hot eyes on Amaryl market.

The domestic pharmaceutical companies are keenly interests in the Amaryl (glymepiride: a anti-diabetic drug) market since the patent protection already expired in Korea and its post market surveillance (PMS) also ended at coming July this year. Its market size as a single item grew up tremendously recording about 42 billion won last year and 60 billion won this year.

According to a reliable ...